Payment overview · 2025
General Payments
$744.96
46 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Michael Earnhardt, MD
Allopathic & Osteopathic Physicians|Family Medicine · MINDEN, LA · NPI 1699762948
Verified facts
What the public records show
CMS Open Payments records show Christopher Michael Earnhardt, MD received $744.96 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Linzess, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.38 | 35.6% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $184.60 | 24.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.79 | 11.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.41 | 6.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.21 | 2.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.59 | 2.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.02 | 2.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.60 | 2.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.18 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.08 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.73 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.07 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.30 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $744.96 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.00 | 12 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $130.79 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $130.79 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $130.79 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.15 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.15 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.87 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.81 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.26 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $2.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 127 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 292 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 346 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 388 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
439 | 91 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
388 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
127 | 127 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
292 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
54 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1331 | 329 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1286 | 341 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1222 | 319 |
| Pantoprazole Sodium | Pantoprazole Sodium | 975 | 243 |
| Lisinopril | Lisinopril | 813 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 720 | 171 |
| Gabapentin | Gabapentin | 682 | 172 |
| Potassium Chloride | Potassium Chloride | 678 | 179 |
| Metoprolol Succinate | Metoprolol Succinate | 612 | 154 |
| Prednisone | Prednisone | 603 | 366 |
| Fluticasone Propionate | Fluticasone Propionate | 595 | 241 |
| Valsartan | Valsartan | 585 | 156 |
| Trazodone Hcl | Trazodone Hcl | 577 | 143 |
| Hydrochlorothiazide | Hydrochlorothiazide | 520 | 149 |
| Omeprazole | Omeprazole | 515 | 136 |
| Clopidogrel | Clopidogrel Bisulfate | 473 | 121 |
| Duloxetine Hcl | Duloxetine Hcl | 469 | 109 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 465 | 122 |
| Montelukast Sodium | Montelukast Sodium | 461 | 113 |
| Mounjaro | Tirzepatide | 445 | 82 |
| Farxiga | Dapagliflozin Propanediol | 439 | 91 |
| Metformin Hcl Er | Metformin Hcl | 427 | 125 |
| Furosemide | Furosemide | 414 | 113 |
| Escitalopram Oxalate | Escitalopram Oxalate | 409 | 88 |
| Ozempic | Semaglutide | 388 | 74 |
| Metformin Hcl | Metformin Hcl | 351 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 349 | 86 |
| Jardiance | Empagliflozin | 346 | 65 |
| Losartan Potassium | Losartan Potassium | 322 | 80 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 319 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 307 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 83 |
| Celecoxib | Celecoxib | 302 | 143 |
| Eliquis | Apixaban | 292 | 61 |
| Sertraline Hcl | Sertraline Hcl | 289 | 69 |
| Azelastine Hcl | Azelastine Hcl | 284 | 136 |
| Spironolactone | Spironolactone | 269 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 59 |
| Allopurinol | Allopurinol | 244 | 59 |
| Simvastatin | Simvastatin | 241 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 236 | 61 |
| Mirtazapine | Mirtazapine | 231 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 217 | 60 |
| Meloxicam | Meloxicam | 211 | 70 |
| Tramadol Hcl | Tramadol Hcl | 204 | 65 |
| Carvedilol | Carvedilol | 195 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 193 | 160 |
| Methylprednisolone | Methylprednisolone | 193 | 155 |
| Atenolol | Atenolol | 185 | 50 |
| Ondansetron Odt | Ondansetron | 182 | 75 |
| Famotidine | Famotidine | 169 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 161 | 136 |
| Bupropion Xl | Bupropion Hcl | 152 | 35 |
| Finasteride | Finasteride | 150 | 33 |
| Myrbetriq | Mirabegron | 149 | 33 |
| Glimepiride | Glimepiride | 144 | 40 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 139 | 116 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 138 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 137 | 28 |
| Azithromycin | Azithromycin | 136 | 107 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 136 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 130 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 128 | 81 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 127 | 127 |
| Donepezil Hcl | Donepezil Hcl | 127 | 24 |
| Ezetimibe | Ezetimibe | 125 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 115 | 24 |
| Fluconazole | Fluconazole | 113 | 74 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 113 | 21 |
| Januvia | Sitagliptin Phosphate | 110 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 105 | 84 |
| Buspirone Hcl | Buspirone Hcl | 102 | 21 |
| Xarelto | Rivaroxaban | 101 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 100 | 19 |
| Risperidone | Risperidone | 100 | suppressed |
| Nifedipine Er | Nifedipine | 98 | 29 |
| Levetiracetam | Levetiracetam | 94 | 17 |
| Irbesartan | Irbesartan | 92 | 21 |
| Pregabalin | Pregabalin | 90 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 90 | 29 |
| Chlorthalidone | Chlorthalidone | 88 | 21 |
| Linzess | Linaclotide | 87 | 21 |
| Lovastatin | Lovastatin | 87 | 20 |
| Cefdinir | Cefdinir | 84 | 67 |
| Clonidine Hcl | Clonidine Hcl | 84 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 84 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 15 |
| Doxepin Hcl | Doxepin Hcl | 81 | 22 |
| Baclofen | Baclofen | 77 | 13 |
| Methocarbamol | Methocarbamol | 77 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 19 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 76 | 24 |
| Clonazepam | Clonazepam | 75 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 19 |
| Trulicity | Dulaglutide | 73 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 18 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 70 | 70 |
| Entresto | Sacubitril/Valsartan | 70 | 14 |
| Meclizine Hcl | Meclizine Hcl | 70 | 26 |
| Memantine Hcl | Memantine Hcl | 69 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 17 |
| Valacyclovir | Valacyclovir Hcl | 64 | 31 |
| Terbinafine Hcl | Terbinafine Hcl | 62 | 57 |
| Enalapril Maleate | Enalapril Maleate | 61 | suppressed |
| Nystatin | Nystatin | 59 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 53 |
| Alendronate Sodium | Alendronate Sodium | 53 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 53 | 18 |
| Mupirocin | Mupirocin | 53 | 32 |
| Warfarin Sodium | Warfarin Sodium | 53 | 13 |
| Glipizide | Glipizide | 52 | 12 |
| Bumetanide | Bumetanide | 51 | 11 |
| Telmisartan | Telmisartan | 51 | 14 |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Colchicine | Colchicine | 47 | 23 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 47 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 46 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | 14 |
| Estradiol | Estradiol | 45 | 15 |
| Glipizide Er | Glipizide | 45 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 44 | 41 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 12 |
| Galantamine Er | Galantamine Hbr | 43 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 42 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 14 |
| Risedronate Sodium | Risedronate Sodium | 41 | 14 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 23 |
| Topiramate | Topiramate | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 26 |
| Dutasteride | Dutasteride | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | 16 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Moxifloxacin | Moxifloxacin Hcl | 22 | 20 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 11 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ubrelvy | Ubrogepant | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Metolazone | Metolazone | 14 | 12 |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tri-Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $744.96 · 46 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, JARDIANCE, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Qelbree, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error